Certolizumab Pegol

Patients with rheumatoid arthritis and high rheumatoid factor demonstrate better clinical outcomes, and maintain drug concentration, when treated with certolizumab pegol vs. adalimumab, according to data published in Rheumatology.

Patients with rheumatoid arthritis who receive abatacept or certolizumab pegol achieve clinical remission at higher rates than those receiving active conventional therapy, according to data published in Annals of the Rheumatic Diseases.

In patients with non-radiographic axial spondyloarthritis, MRI sacroiliitis and HLA-B27 positivity, but not elevated C-reactive protein or responses at week 12, predict long-term certolizumab pegol response, according to data.

Patients dosed with certolizumab pegol for moderate to severe plaque psoriasis achieved and maintained absolute Psoriasis Area and Severity Index thresholds, according to an analysis at the American Academy of Dermatology virtual meeting.

ATLANTA — Certolizumab pegol and bimekizumab were associated with improvements ranging from work productivity to disease activity in patients with spondyloarthritic conditions, according to findings presented in three abstracts at ACR/ARP 2019.

Patients with psoriatic arthritis showed long-term efficacy and safety with Cimzia by achieving Disease Activity Index for Psoriatic Arthritis minimal disease activity and very low disease activity in the 4-year RAPID-PsA phase 3 trial, according to results presented at the European Academy of Dermatology and Venereology Congress.